CORPORATE INVESTOR PRESENTATION - April 2021
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
CORPORATE INVESTOR PRESENTATION
April 2021
Contents
roduction to BioHarvest
Market Opportunity
Company Competitive Advantage
Financials
2
Introduction to
BioHarvest
3
The confluence of food-tech, biotech, health &
WELLNESS and sustainability.
Leading Biotech Innovation Across the Plant
Kingdom 4
BioHarvest - Executive Summary First and only fully validated industrial scale plant cell technology platform (Biofarming) for the Non GMO production of a plant’s active ingredients without growing the plant itself. Addressing $500B of multiple Plant Based verticals that include Nutraceuticals, Cannabinoids, Proteins and Cosmeceuticals. Highly experienced management team and advisory board focused on creating shareholder value by executing flawlessly in the Nutraceutical (super fruits) and Cannabis markets. Successfully Implemented the BioFarming platform technology with GMP and ISO certified production processes and has commercially produced VINIA ® (the only nutraceutical containing Piceid Resveratrol from red grapes skin). Science driven company with all health related claims supported by clinical trials published in peer reviewed scientific journals. Successfully Launched VINIA® using D2C in Israel and planning to do the same shortly in the US. Completing shortly the construction of a 20 Tons per year production facility (low capex
BioHarvest - Executive Summary
Groundbreaking R&D progress with Cannabis
Only company to announce ability to optimize Trichome growth across multiple cannabis strains.
First company to successfully grow Cannabis cells (in suspension / liquid-media), and produce six distinct cannabinoid molecules
- THCA, THC, CBDA, CBD, CBN, CBC - identical to the cannabinoids produced by the plant.
No other research group has been able to grow Cannabis plant cells in suspension (liquid media) in bioreactors.
Low-cost, GMP and ISO certified, fingerprint consistency source of full spectrum clean Cannabis at industrial scale with all
parameters that are key to the Pharma and CPG industries.
In process of driving commercialization of Cannabis products to market in 2022.
Company’s BioFarming technology is unrivaled in its sustainability credentials from a land use, water efficiency and free of
solvents/pesticides.
6
Key Milestones
• Established a dedicated Cannabis R&D program and obtained a Cannabis
R&D license from the Israeli Ministry of Health
• Fully installed a certified R&D Lab for Cannabis
• Performed comprehensive screening of Cannabis strains and plant material.
• Achieved industrial scale plant cell growth and commercial GMP • Induced Cannabis cells to grow on both solid media and in
production of VINIA® (proprietary / patented red grape based suspension (liquid media), and successfully produced Cannabis
Resveratrol product) trichomes
• Clinical research validating high bioavailability and efficacy for VINIA® • First company to stably grow Cannabis cells in suspension, and
produce six distinct cannabinoid molecules - THCA, THC, CBDA,
• Expression of complex secondary metabolite compounds and process CBD, CBN, CBC – with an identical cannabinoids profile to that
scale-up for other plant cells including pomegranate, olives and of the source plant
blueberries
7
Key Milestones
• First company to produce cannabis cells in small • Will Convert current 2 Ton per Year production
bioreactors facility (in Israel) to Cannabis
• Q2- Will Commence VINIA® Sales in the US
• Obtained Israeli Ministry of Health approval to install
and grow Cannabis cells in 20 medium and large • Q3 – Will bring 20 Ton industrial-scale facility for
scale bioreactors VINA® (in Israel) online
• Scale-up process for growing Cannabis cells in medium and large industrial bioreactors
• Signed a major Vinia B2B distribution agreement in the US (received our first order)
• Established 20 Ton per year Vinia production / manufacturing partnership
• Successfully resumed VINIA® Sales in Israel in November 2020 (> $100k monthly)
8
2021 Milestones
1 2 3
DELIVER DISRUPTIVE D2C VINIA PARTNER WITH BATORY FOODS TO COMPLETE FULL “SCALE UP” OF
LAUNCH IN THE US BUILD PARTNERSHIP WITH 5 MAJOR CANNABIS TECHNOLOGY TO ENABLE
LEADERSHIP COMPANIES IN FOOD & MARKET ENTRY IN H1 2022
NUTRACEUTICAL WORLD
4 5 6
ACCELERATE REGULATION ROLL DEVELOP AND EXECUTE SCIENTIFIC IMPLEMENT A SUSTAINABILITY
OUT FOR VINIA® AND SUPERFRUIT VALIDATION ROADMAP TO DRIVE FRAMEWORK, BENCHMARK VERSUS
PIPELINE FURTHER DIFFERENTIATION COMPETITION & DRIVE 3RD PARTY
VALIDATION OF SUSTAINABILITY
ADVANTAGES
9
Current Executive Team has Extensive Experience in Operating
Disruptive R & D Driven Companies
Yochi Hagay
Ilan Sobel CTO
CEO
Ilan Sobel, brings to the Company extensive experience in General Dr. Yochi Hagay, Ph.D., is CTO of BioHarvest Ltd and formerly served as Chief
Management, International Sales and Marketing, Manufacturing and Executive Officer. She has extensive experience in leading research and
Operations, which included 18 years leading international businesses for development in the pharmaceutical and bio-tech industry. Ms. Hagay served in
the Coca Cola Company. Previous to joining BioHarvest, Ilan served as various positions in BTG for 15 years, until it was acquired by Savient. In her
Chief Operating Officer and transitioned to Chief Commercial Officer of most recent role at Savient (2002-2005), she supervised the company’s clinical
Weissbeerger for the last 2 years. In these roles, Ilan played a major studies. Ms. Hagay holds a PhD in biotechnology from Hebrew University
leadership role in building a disruptive BIG Data, IOT & Software Company (2004).
servicing major Beverage players which was purchased by Anheuser Busch
InBev.
Zaki Rakib
President and Chairman of the Board Malkit Azachi
VP R&D
Dr. Zaki Rakib, Ph.D., serves as the President and Chairman of
BioHarvest. He is a serial entrepreneur who founded Terayon Dr. Azachi, Ph.D., brings nearly 20 years of experience in
Communications Systems in California in 1994, took it public on biochemistry, genetic engineering, tissue culture, molecular
the NASDAQ in 1998 and led it as the CEO (from inception) to a biology, and clinical & pre-clinical trials. Prior to BioHarvest, Dr.
market cap over $7B in 2000. He is currently focusing on the Azachi served as technology Director at HealOr Ltd, a
business development aspects of BioHarvest, and particularly Biopharmaceutical company developing topical therapeutics.
for exploring new verticals to leverage the proprietary
BioFarming technology.
10Current Executive Team has Extensive Experience in Operating
Disruptive R & D Driven Companies
Nat Averill Michal Sapir
Vice President Manufacturing and Quality VP Regulation Affairs
Assurance
Michal Sapir brings 30 years of experience in the medical
Nathaniel Averill has over 25 years of experience in biotech device, pharma and biotechnology industries. Prior to joining
pharmaceutical manufacturing. His expertise includes BioHarvest, Mrs. Sapir served as Senior Director of Project
design, startup, and management of biotech facilities with Management at ColBar LifeScience Ltd., a Johnson & Johnson
companies such as Abbott Bioresearch Center, MedImmune Company. Mrs. Sapir has broad experience in clinical and
Inc., and Bristol-Myers Squib. He was instrumental in the animal studies; she served as Affiliate Quality Coordinator &
development and production of a number of blockbuster Senior Clinical Research Administrator in Eli Lilly (1995-
drugs including HUMIRA® (Adalimumab) and ORENCIA® 2000).Michal Holds a Master of Science in Biochemistry from
(abatacept). Nathaniel also has expertise in remediation of Bar Ilan University, Israel.
compliance risks to approval of Federal Drug Administration
(FDA), European Medicines Agency (EMEA), and other
regulatory agencies.
11Scientific Advisory Team
Dr. David Brady Dr. Dennis Goodman
Dr. Brady brings to the advisory board 30 years of Dr. Goodman (M.D., F.A.C.C., F.A.C.P., F.C.C.P) brings over 40
experience as an integrative and nutritional medicine years of relevant medical experience across multiple
practitioner and over 25 years in health sciences disciplines, including preventive cardiology. Dr. Goodman
academia. He is a licensed naturopathic medical currently serves as Clinical Professor of Medicine at the New
physician in Connecticut and Vermont, is board York School of Medicine, Professor of Medicine at the
certified in functional medicine and clinical nutrition, University of Cape Town, Director of Integrative Medicine
and is a fellow of the American College of Nutrition. and Preventive Cardiology at the New York School of
Dr. Brady has been the Chief Medical Officer of Medicine. Dr. Goodman has participated in over 50 clinical
Designs for Health, Inc. and currently serves as the trials and has extensive experience in providing advisory
Chief Medical Officer for Diagnostic Solutions Labs, services in this highly technical area.
LLC.
12Advisory Team
Eitan Popper B.Sc., M.Sc, MBA Adv. Roberto Chait LLB
Chairman of the Board of Advisors
Mr. Chait brings to the Company a wealth of experience in
Mr. Popper was the co-founder and President of MedReleaf Corp., which was
corporate and international trade law, intellectual property
acquired in 2018 for $2.5 billion USD, in what was the largest Cannabis industry law, and cross border international transactions. His
exit to date. Prior to its acquisition, MedReleaf was one of the largest and most knowledge and expertise in these areas have been acquired
reputable vertically integrated medical Cannabis producers in the world. Mr. representing major global clients across highly relevant
Popper brings over 15 years of international partnerships, entrepreneurial industries including Food and Beverage, Food Tech, and
ventures, disruptive industry, large-scale project development, engineering and International Media..
investment experience.
Scott McCune
Prior to founding McCune Sports & Entertainment Ventures (“MS&EV”), LLC, Scott had a successful 30-year career with the Coca-Cola Company
and Anheuser-Busch Inc. where he gained significant skills and experience building global brands, leading and inspiring diverse organizations,
planning and executing complex operations, innovating new approaches to the business, negotiating and maximizing partnerships, driving
productivity and managing P&Ls. Scott led Coca-Cola’s global strategies and organizations for integrated marketing, media, interactive,
experiential, sports and entertainment marketing, licensing, global events and partnerships.
Rhona Applebaum, PH.D.
Serving most recently as the Coca-Cola Company first Chief Science and Health Officer, Rhona developed and executed the Company’s global
health and well-being strategy. Previously Rhona was executive VP and Chief Science Officer for the National Food Processors Association
(NFPA). Rhona has held numerous high-level public assignments, with service on the US Department of State’s Advisory Committee on
International and Economic Policy, CDC Foundation’s Roundtable on Global Health Threats, the Harvard Medical School Global Health Advisory
Council, Center for Strategic & International Studies Commission on Smart Global Health Policy and various Advisory Boards for the USFDA and
USDA.
13Market
Opportunity
$ $ $
$ $ $
$ $ $ $
$ $ $ $
$ $ $
$ $ $ $ $ $ $
$ $ $ $
$
$ $ $ $ $ $ $ $ $ $
Nutraceuticals Cannabinoids Proteins Flavors and Cosmeceuticals
Fragrances 14Nutraceutical Market Sizeable and Growing as Consumer
Health & Wellness Consciousness Peaks
B2C B2B
OPERATING IN A 100 BILLION $ MARKET FOR DIETARY FOCUSED ON FOOD, DIETARY SUPPLEMENT AND BEVERAGES
SUPPLEMENTS MARKET OF 110 BILLION
15Cannabis at the Forefront of Alternative Therapies
Emergence of Cannabis and major cannabinoids (THC & CBD) into the mainstream has ignited an influx of innovation, capital
and soaring valuations, while stirring the pot of social change
Global Cannabis sales reached $9.5 billion in 2017 and
are projected to surpass $100 billion in 2024 NEW CHART
COMING
North American market alone is expected to surpass
$40 billion in sales by 2025, with a 20+% CAGR, based
on conservative estimates
Legalization is quickly spreading
> 90% of Americans support legalizing Cannabis for
medical purposes
35 US states have fully legalized medical Cannabis
> 30 countries have implemented medical Cannabis laws
95% of the US population lives in states with
access to medical Cannabis
16Current Cannabis Industry Constraints and Inefficiencies
Capital Intensive (High Capex)
Labor Intensive (High Opex)
Production is Seasonal and Weather Dependent
Product Quality and Consistency Challenges
Production is Susceptible to Contamination (i.e. Pesticides, Heavy Metals, Fungi)
Production Processes and / or Products are Not Proprietary or Patent Protected
Impractical for Minor Cannabinoids
Substantial Environmental Footprint
17Big Pharma Watching from the Sidelines but Significant Pharma
Companies looking for Next Generation Cannabis Driven Drugs
Big Pharma has been slow to participate in a meaningful way, mainly deterred by
regulatory and IP protection concerns
Only one player has actively participated - GW Pharmaceuticals (acquired early 2021
by Jazz Pharmaceuticals for $7.2B )
Acquired for: $7.2 Billion
Launched first FDA approved plant-derived Cannabinoid drug in November of 2018 -
Epidiolex® (Cannabidiol / CBD)
Rapid growth within 6 months of launch; $102M net sales in H1 2019
2020 Epidiolex global net product sales increased over 70% to $510m (2019: $296m)
Favorable payor coverage in commercial, Medicare and Medicaid
18BioHarvest
Sciences Inc:
Competitive
Advantage
19Disruptive Technology - Bridging the Gap
BioHarvest’s technology platform represents an efficient, proprietary, and IP protected means to produce plant
based compounds including whole spectrum Cannabis, cannabinoids or Cannabis derivatives, which could have
profound implications for the Cannabis industry, disrupt the supply chain, reduce cost, and most importantly – bridge
the gap between the current traditional Cannabis supply for big pharma and Consumer Packaged Goods (CPG)
Continuous and Repeatable, Capital Efficient, and Scalable Technology
Orders-of-Magnitude Reduction in Resource and Footprint Requirements
Production of Minor Cannabinoids Is Just as Feasible as the Production of Major Cannabinoids
Superior Finished Product Purity and Quality Control
Production Processes and Finished Product are Proprietary and are Patent Protected
Process Control Capabilities on Par with Pharma-standard Quality
Assurance Protocols
Unparalleled Environmental Sustainability
20Assets / Strengths
Robust Technology Platform Scientifically Validated Claims which can be translated
into Consumer Facing Messaging on Package
Successful Plant Metabolite Elicitation (increasing
target ingredient concentrations by orders of
magnitude Commercial / Cost Efficient Production and Sales of
Existing Products
Proprietary and Patent Protected IP
Unique and Disruptive Milestones with Cannabis
Cells and SuperFruit Nutraceutical Pipeline
Scaled-up, GMP and ISO Certified Production Process
Proven Commercial Capabilities and Track Record to
translate R&D into Revenue (VINIA® ) with successful
Israel E-Commerce launch
21Patent Portfolio Enhanced by Proprietary “Know How”
Robust Patent Portfolio
Over 17 patents filed to date
14 patents already granted in 5
different jurisdictions
- Process
- Scaled Up Technology
- Product Composition
- Treatment of Diseases/Applications
22The Process
Click for Video on the BioFarming Process
23Successful Plant Metabolite Elicitation
Metabolite Elicitation = Increased Concentration
Orders of magnitude increase of the relevant compound / active ingredient concentration
100x increase of the concentration of Resveratrol, when compared to the concentration in nature
Elimination of sugar, calories and alcohol
24Significant Scientific Validation
BioHarvest’s technology platform and products BioHarvest has conducted several clinical trials at independent institutions
showing that VINIA is the first ever Natural Vasodilator Without Sugar or
have been scientifically validated as safe, Calories
efficacious, and highly bioavailable.
VINIA - BioHarvest’s red grape Resveratrol product -
has undergone in-vitro studies, pre-clinical trials,
and clinical trials that support structural and
functional claims, and is Generally Recognized As
Safe (GRAS) in compliance with the FDA.
A total of 8 Scientific Studies were performed with
VINIA and 3 peer reviewed Scientific papers have
been published. The VINIA marketing
concept is simple for the
consumer to understand
as it is based on the well
known French paradox
which consists of the
benefit of drinking red
wine to improve cardio
vascular health, despite
very high fatty diets.
25VINIA®’s FDA guidelines based Structure/function claims
1. VINIA ® Supports Heart Health by improving blood flow and delivery of oxygen
2. VINIA ® Increases Dilation of Arteries and Blood Vessels
3. VINIA ® Supports Healthy Arteries
4. VINIA ® Supports Blood Circulation
5. VINIA ® Supports Blood Pressure already within Normal Range
6. VINIA ® Fuels Antioxidant activity within your Veins and Arteries
7. VINIA® Improves Physical Energy and Mental Alertness via the delivery of increased blood flow
and oxygen to the body’s tissues and organs
26Build “Best in Class” High Margin Direct to Consumer Marketing
Model & “Pipes” into US Households to layer additional Portfolio
Phased Geographic Roll-Out based on Optimization to 60M + Target Population Build a Direct 2 Consumer (D2C) Route to Market for VINIA and Pipeline
(40+ Age Profile – 40% of USA Population)
South East North East Pacific
Lead Category Narrative with Consumers demonstrating VINIA’s Superiority and Core Surgically Deploy a Best in Class E-Commerce Driven Marketing Mix to Core Target
Sustainable Competitive Advantage Market
FLORIDA’S – BABY
40+ Mainstream Consumers 40+ Christian Market
BOOM
GENERATION (July GIVE YOURSELF
THE GIFT OF LIFE
1,2019) from t h e lan d of ZION
The Israeli Superfood
m ad e from Red Grap e Cells from ZION w h ich
su p p ort s a h ealt h y h eart an d im p roved b lood
circu lat ion an d en h an ces you r vit alit y an d alert n ess
via t h e im p roved con d u ct ion of oxyg en .
Stop drinking only water, and use a little
wine because of
27VINIA® will also be leveraged into other Major High Margin Categories
Dietary Supplement Health Bar
Global
Market $ 12 Billion USD* $ 25 Billion USD*
Size *Source: Persistence Market Research 2020 Dietary Supplements Report *Source: A2Z Market Research Market Research, 2020 based on US
28
Heart Health and Energy Related Supplements being USD 10 Billion market and 40% of Global MarketWe have a Pipeline of Nutraceutical Superfruits to
bring to market
H2 2022 H2 2023
• Maintenance of normal blood HDL- • Anti-inflammatory Support
cholesterol concentrations
OLIVIA and POMIA Trademarks are WIP names
29Groundbreaking Cannabis R&D Progress
1. Six distinct Cannabinoids (THCA, THC, CBDA, CBD, 3. Cannabinoid profile
CBN, CBC) produced by Cannabis cells through BioHarvest’s produced by Cannabis grown in
technology. suspension (liquid media) – is
identical to the profile of the
source Cannabis plant.
2. First Company to have successfully 4. Developed unique process to
grown Cannabis cells containing optimize production of trichomes
Cannabinoids - using small scale in liquid media
bioreactors.
Cannabis trichomes produced by
BioFarming compared to plant trichomes
30Our Competitive Advantage across Key Dimensions
31Cannabis upcoming milestones
Complete development of Cannabis – H2 2021
Convert existing 2 Ton per Year Vinia facility to Cannabis – H2 2021
Submit “Cannabis dossier” to the Israeli Ministry of Health – H2 2021
First sales of Cannabis cells in Israel – H1 2022
Submit product dossier to the relevant authorities in N.A. --- H1 2022
32FOCUSED ON IMPLEMENTING A SUSTAINABILITY FRAMEWORK, BENCHMARKING
VERSUS INDUSTRY & DRIVING 3RD PARTY VALIDATION
BioFarming has major sustainability advantage versus other industry players in Cannabis and
Botanical Nutraceuticals
Currently Developing Environmental, Social and Governance (ESG) Reporting across the
Business
Have identified Sustainability Framework and Reporting Methodology
Benchmarking our Performance versus Industry and Peers
• Carbon Footprint,
• Land, Water, Energy Use,
• Social Governance
Defining clear Goals/KPI’s as part of 3 & 5 year plan
Drive 3rd Party Validation and Endorsement
Plan to Initiate Effective Communication with Stakeholders in Q3, 2021
33Future Verticals to leverage the BioFarming Technology
Plant based Growth Factors Proteins for the cultivated meat industry
High cost plant based Pharmaceutical API’s
Plant based Cosmeceuticals
Rare plant based fragrances
34Appendix:
Clinical Studies
41VINIA in clinical trials demonstrated its ability to significantly increase Flow Mediated Dilation-
i.e. Elasticity of Blood vessels (by up to +148% vs baseline)
42PICEID RESVERATROL GIVES VINIA® A UNIQUE AND SIGNIFICANTLY
SUPERIOR CHEMICAL STRUCTURE
VINIA Red grape Piceid-Resveratrol
25.5 X MORE
Piceid (t-resveratrol glycoside) WATER
Isolated Resveratrol (NAKED)
SOLUBLE
t-Resveratrol 1https://pubchem.ncbi.nlm.nih.gov/compound/445154#section=Melting-Point
2. https://go.drugbank.com/drugs/DB11263
3. https://www.scbt.com/p/polydatin-65914-17-2VINIA® BIO-AVAILABILITY DELIVERS QUICKLY & IS LONG
LASTING FOR 12 HOURS
Azachi M et al, 2014, Int J Food Sci Nutr. 65 (7) 848-55VINIA in clinical trials demonstrated its
ability to promote heart health via Anti-
Oxidant activity. VINIA inhibits
oxidation of blood lipids including LDL
Cholesterol
*PYou can also read
